Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

dc.contributor.authorSoldevila-Boixader, Laura
dc.contributor.authorVillanueva, Bernat
dc.contributor.authorUlldemolins, Marta
dc.contributor.authorBenavent Palomares, Eva
dc.contributor.authorPadullés Zamora, Ariadna
dc.contributor.authorRibera Puig, Alba
dc.contributor.authorBorras, Irene
dc.contributor.authorAriza Cardenal, Javier
dc.contributor.authorMurillo Rubio, Óscar
dc.date.accessioned2021-05-13T12:46:30Z
dc.date.available2021-05-13T12:46:30Z
dc.date.issued2021-04-16
dc.date.updated2021-05-13T12:11:38Z
dc.description.abstractBackground: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients ≥70 years (8.1%). The risk factors for DEP were age ≥70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin ≥10 g (5.30, 1.14-24.66). Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec720014
dc.identifier.pmid33923382
dc.identifier.urihttps://hdl.handle.net/2445/177264
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/antibiotics10040446
dc.relation.ispartofAntibiotics, 2021, vol. 10, num. 4
dc.relation.urihttps://doi.org/10.3390/antibiotics10040446
dc.rightscc by (c) Soldevila et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationPneumònia
dc.subject.classificationMalalties bacterianes grampositives
dc.subject.otherPneumonia
dc.subject.otherGram-positive bacterial infections
dc.titleRisk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
antibiotics-10-00446.pdf
Mida:
401.29 KB
Format:
Adobe Portable Document Format